Beth Israel Deaconess Medical Center, Inc.

Applied Research Systems Ars Holding N.v.

Wlodzimierz Maslinski

Terry Barton Strom

Xin Xiao Zheng

Yon Su Kim

Sylvie Ferrari-Lacraz

Disclosed herein are mutant IL-15 polypeptides and methods for using these polypeptides to modulate the immune response in a patient.

Antagonists of interleukin-15

Disclosed herein are therapeutic compositions containing agents that modulate the immune response in a patient.

Compositions and methods for achieving immune suppression

Disclosure herein are mutant IL-15 polypeptides and methods for using these polypeptides to modulate the immune response in a patient.

Nucleic acids encoding antagonists of interleukin-15

The invention relates to compounds, such as proteins, peptides and organic compounds, capable of blocking or inhibiting the binding interaction of Raf-1 or 14-3-3 proteins to the &bgr; chain of IL-2, and pharmaceutical compositions containing such compounds. In vitro assays for isolating, identifying and characterizing such compound capable of inhibiting interaction of Raf-1 or 14-3-3 proteins to IL-2&bgr; are also provided.

Growing community of inventors

Warsaw, Poland

Wlodzimierz Maslinski